CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments
CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues.
CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer.